Polyneuropathy in patients with continuous levodopa/carbidopa intestinal gel (LCIG) infusion
Objective: To assess frequency of polyneuropathy in patients with LCIG and the usefulness of routine nerve conduction studies follow-up Background: Continuous levodopa infusion is an…Utilization patterns of Amantadine in Parkinson’s Disease patients enrolled in the French COPARK study
Objective: To explore amantadine IR utilization patterns in the French COPARK study. Background: Immediate release (IR) amantadine is marketed for the treatment of early and…BouNDless: An active-controlled randomized, double-blind double-dummy study of continuous ND0612 infusion in patients with fluctuating Parkinson’s disease
Objective: Determine the efficacy, safety, and tolerability of continuous subcutaneous ND0612 infusion in comparison to oral Carbidopa/Levodopa (CD/LD) in patients with Parkinson’s disease (PD) experiencing…Outcomes of the first-in-human study with a recombinant botulinum toxin E (rBoNT-E): safety and pharmacodynamic profile of rBoNT-E compared with abobotulinumtoxinA
Objective: To evaluate safety and pharmacodynamic (PD) profiles of the first recombinant botulinum toxins (BoNT) serotype E (rBoNT-E) versus abobotulinumtoxinA (aboBoNT-A) in healthy male volunteers.…A single nigral injection of human ENGRAILED-1 induces long-lasting behavior benefit in an experimental primate model of Parkinson Disease
Objective: Evaluate the efficacy of a single nigral injection of human ENGRAILED-1 (hEN1) in a recognized chronic MPTP macaque model. Background: EN1 homeoprotein has been…Evaluation of neuroprotection by human ENGRAILED-1 in a chronic AAV-hα-synuclein-A53T (AAV-A53T) rat model of Parkinson Disease
Objective: Investigate the long-term neuroprotective effect of a single bilateral injection of human ENGRAILED1 (hEN1) in a rat α-synuclein model of Parkinson Disease (PD). Background:…Unilateral delivery of cell-based therapy to the putamen and substantia nigra in patients with Parkinson’s disease who have an existing DBS system
Objective: Evaluate the safety and feasibility of unilateral cell-based therapy delivery to the putamen and substantia nigra in patients with Parkinson’s disease (PD) undergoing deep…Management of Akinesia in Parkinson’s Disease with Apomorphine Subcutaneous Injection
Objective: To assess the effect of apomorphine on time-to-ON in PD patients with morning akinesia. Background: In patients with motor fluctuations complicating Parkinson's disease (PD), delays in time-to-ON…The relationship between sound pressure level (SPL) and speech intelligibility in Parkinson’s disease following intensive speech treatment: LSVT LOUD and LSVT ARTIC
Objective: The relationship between the acoustic measure SPL (correlate of vocal loudness) and ratings of speech intelligibility was studied in fifty-seven individuals with Parkinson's disease…The French NS-PARK/FCRIN network: a 5-year balance sheet
Objective: To describe the achievements of the French NS-PARK/FCRIN network (http://www.parkinson.network/) after 5 years of activity. Background: The French Clinical Research Infrastructure network FCRIN is…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.